Posts Tagged ‘CoQ10 deficiency’

  • Treatment of Heart Disease with Coenzyme Q10

    Date: 2007.11.29 | Category: Heart Tips | Response: 0

    Since its discovery in the late 1950s Coenzyme Q10 (CoQ10) has received much attention as a necessary compound for proper cellular function. It is the essential coenzyme necessary for the production of ATP (adenosine triphosphate) upon which all cellular functions depend. Without ATP our bodies cannot function properly. Without CoQ10, ATP cannot function. This connection has made CoQ10 a very important object of study in relation to chronic disease. In many cases the presence of chronic disease is associated with inadequate levels of CoQ10. But no area of study has received more attention than the relation between CoQ10 and heart disease. That is because CoQ10 is believed to be of fundamental importance in cells with high metabolic demands such as cardiac cells. A further reason the connection of heart disease and CoQ10 has gained so much attention is because heart conditions of many kinds are associated with chronically low CoQ10 levels.

    CoQ10 is highly concentrated in heart muscle cells because of their high energy requirements. Add this to the fact that heart disease is the number one killer in developed and developing countries and one can see why the bulk of scientific research on CoQ10 has been concerned with heart disease. Specifically, studies on congestive heart failure have demonstrated a strong correlation between the severity of heart failure and the degree of CoQ10 deficiency. The lower the levels of CoQ10 in the heart muscles the more severe the heart failure. If indeed CoQ10 deficiency is a primary cause of congestive heart failure then, in such cases, the remedy is simple and cost effective; CoQ10 supplementation.

    Congestive heart failure is a condition where the heart does not pump effectively resulting in an accumulation of fluid in the lungs. Symptoms may include shortness of breath, difficulty breathing when lying flat and leg or ankle swelling. Causes include chronic hypertension, cardiomyopathy (primary heart disease) and myocardial infarction (irreversible injury to heart muscles). Heart muscle strength is measure by the ejection fraction which is a measure of the fraction of blood pumped out of the heart with each beat. A low ejection fraction indicates a weak heart.

    Several trials have been conducted involving patients with enlarged weak heart muscles of unknown causes. For those of you who like difficult phrases this condition (or variety of conditions) is known as idiopathic dilated cardiomyopathy. In these trials CoQ10 supplementation was compared to placebo effects. Standard treatments for heart failure were not discontinued. The results were measured by echocardiography (a diagnostic test which uses ultrasound waves to make images of the heart chambers, valves and surrounding structures). The overall results of CoQ10 supplementation demonstrated a steady and continued improvement in heart function as well as steady and continued reduction in patient symptoms including fatigue, chest pains, palpitations and breathing difficulty. Patients with more establish and long-term cases showed gradual improvement but did not gain normal heart function. Patients with newer cases of heart failure demonstrated much more rapid improvement often returning to normal heart function.

    Papers numbering in the hundreds from eight different symposia have been written and presented on the effects of CoQ10 on heart disease. International clinical studies have also been conducted in the United States, Japan, Germany, Italy and Sweden. Together these studies and the papers that have been derived from them demonstrate significant improvement in heart muscle function while causing no adverse effects.

    One particular area of study involves diastolic dysfunction which is one of the earliest signs of myocardial failure. Diastole is the phase of the cardiac cycle when the heart is filled with returning blood. Because this phase requires more cellular energy than the systolic phase (when the blood is pushed out of the heart) it is more dependent on CoQ10. Diastolic dysfunction is a stiffening of the heart muscle which naturally restricts the hearts ability to pump. This condition is associated with many cardiac disorders. Hypertension is among these disorders. As the heart muscles become stiff there is often a corresponding rise in blood pressure. When the diastolic dysfunction is reversed, blood pressure tends to lower as well. In one study involving 109 patients with hypertension, CoQ10 supplementation was added to normal hypertension treatments. In an average of 4.4 months 51% of the patients were able stop using at least one blood pressure lowering medication. Some were able to stop using up to three medications. Another study produced similar results. In that study 43% of 424 patients were able to stop using between one and three cardiovascular drugs because of CoQ10 supplementation.

    These examples are just a drop in the bucket. Diastolic dysfunction (and by proxy, hypertension) includes only a small sampling of heart conditions that respond favorably to CoQ10 supplementation. Other areas of research show great promise for CoQ10 treatments. Among these are cancer and AIDS. But such conditions are beyond the scope of this essay. CoQ10 is essential to the proper functioning of all cell types. It is not surprising, therefore, to find a diverse number of diseases that respond favorably to CoQ10 supplementation. Since all metabolically active tissues are highly sensitive to CoQ10 deficiency, we can expect to see CoQ10 research expand to many other areas of chronic diseases.

    http://www.optimal-heart-health.com/coq10.html

    About the Author

    Greg has degrees in science, divinity and philosophy and is currently an I.T. developer.

    Written By: Greg Post

  • Congestive Heart Failure And CoQ10

    Date: 2007.11.24 | Category: Heart Tips | Response: 0

    Since the 1960s there have been numerous controlled clinical trials concerning the relationship between congestive heart failure and Coenzyme Q10 (CoQ10). As its name implies CoQ10 is a coenzyme that is necessary for the proper functioning of other substances, one of the most important of which is ATP (adenosine triphosphate). ATP is necessary for the production of cellular energy. By proxy CoQ10 is likewise essential for this process.

    Clinical trials have attempted to study the relationship between CoQ10 and many chronic diseases including, but not limited to, heart disease, cancer and AIDS. But heart disease has gained the most attention; congestive heart failure being one of the primary subjects. Because heart muscle cells require so much energy to function and CoQ10 is at the core of the cellular energy process it makes sense to suspect that congestive heart failure might be linked to CoQ10 deficiency. With that theory in mind many studies like the ones that follow have been conducted. These trials have been presented in this essay in thumbnail format.

    One early Japanese trial (1972) involved 197 patients with varying levels of severity of cardiac failure. The study reported significant improvement of cardiac function supplementing with 30 mg per day of CoQ10. Another Japanese study demonstrated similar results with 38 patients also supplementing with 30 mg. In 1985 a U.S. clinical study prescribed daily supplementation with 100 mg of the coenzyme for treatment periods of three months for patients with low ejection fraction measurements. The ejection fraction is the measure of the hearts ability to pump blood. A low ejection fraction is a classic symptom of congestive heart failure. Again, significant improvements in heart function were reported. Other clinical trials followed prescribing the same level of supplementation with similar results.

    Studies in the early 1990s showed improvement for patients suffering from ischemic cardiomyopathy (a low oxygen state usually due to obstruction) with supplemental levels of 200 mg per day. Supplementing with 100 mg per day demonstrated improvement for patients suffering from idiopathic dilated cardiomyopathy, an enlarged heart syndrome of unknown cause.

    One of the largest trials of the 1990s involves 641 patients randomly divided into two groups. The first group received a placebo. The other group received CoQ10 supplements. During the one-year follow-up period 118 patients in the placebo group were hospitalized for heart failure compared to 73 in the group that received the supplements.

    All of the preceding trials were relatively short-term studies. The level of improvement among patients varied depending on how long they had been suffering from some aspect of congestive heart failure. Through the years it has become increasing clear that the greatest improvements were shown in patients that had suffered from their condition the least amount of time. In other words, the longer a person had been suffering from the disease before he or she received CoQ10 treatments the less improvement was demonstrated. People who had received treatments early in the development of the disease showed the most dramatic improvement often returning to normal heart function. Long-term sufferers received less relief and were less likely to return to full heart function. Whatever the reasons for this disparity in health improvement, it demonstrates the importance of receiving treatment as early as possible.

    But what about long-term studies? Do they show the same marked improvement with similar treatment? In the short-term trials it was apparent that even high level supplementing with CoQ10 seemed to produce no ill effects. In order to determine if this is only true for short durations a number of long-term studies were conducted.

    In 1990 observations were published concerning 126 patients with dilated cardiomyopathy. Unlike previously noted studies this one followed the patients progress for six years. Long-term benefits from CoQ10 supplementing were noticed with no harmful side effects. Similar observations were made in a trial involving 2,664 patients treated with CoQ10 at levels up to 150 mg per day.

    A 1994 study involving 424 patients with a variety of myocardial (refers to the heart’s muscle mass) diseases. Among these conditions were the following: Valvular heart disease (pertaining to dysfunction of heart valves), hypertension, diastolic dysfunction (failure of the heart to properly refill itself with blood), dilated cardiomyopathy (group of disorders where the heart muscle is weakened and enlarged and cannot pump effectively) and ischemic cardiomyopathy (low oxygen state usually due to obstruction of the arterial blood supply). Patients were treated with an average of 240 mg of CoQ10 daily during their treatment period. They were then followed-up for up to eight years with an average follow-up period of 18 months. Overall results demonstrated measurable cardiac improvements in one month with maximum improvements at about six months. With continued CoQ10 treatment the improvement in most patients was sustained. However, discontinuing the treatment usually resulted in a decline of cardiac function with eventual return to pre-treatment conditions.

    As always in the medical community many more studies will need to be conducted to determine the future of CoQ10 treatment. However, the research to date seems to support CoQ10 as a viable treatment for many diseases that are caused or exacerbated by inadequate production of cellular energy.

    http://www.optimal-heart-health.com/coq10.html

    About the Author

    Greg has degrees in science, divinity and philosophy and is currently an I.T. developer.

    Written By: Greg Post